Sitagliptin - Merck & Co

Drug Profile

Sitagliptin - Merck & Co

Alternative Names: Glactiv; Januvia; MK-0431; MK-431; ONO-5435; Tesavel; Xelevia

Latest Information Update: 24 Mar 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Merck & Co; Merck Sharp & Dohme
  • Developer Banyu; Merck & Co; Merck Sharp & Dohme; Ono Pharmaceutical; Pfizer; University of Colorado at Denver; Washington University School of Medicine
  • Class Antihyperglycaemics; Pyrazines; Small molecules; Triazoles
  • Mechanism of Action CD26 antigen inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Type 2 diabetes mellitus
  • Discontinued Type 1 diabetes mellitus

Most Recent Events

  • 01 Feb 2018 Merck Sharp and Dohme Corp completes a phase III trial for Type-2 diabetes mellitus (Adjunctive treatment) in Czech Republic (PO) (NCT02791490)
  • 30 Jan 2018 Merck Sharp & Dohme completes a phase III trial for Type-2 diabetes mellitus (Adjunctive treatment) in Estonia, Hungary, Latvia, Spain, Denmark, Poland, USA, Canada (NCT02738879)
  • 01 Jan 2018 Merck initiates enrolment in a phase II trial for Type 2 diabetes mellitus in Germany (PO) (NCT03359590)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top